These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Therapeutic plasma exchange as a therapeutic modality for the treatment of IVIG complications. Welsh KJ; Bai Y J Clin Apher; 2015 Dec; 30(6):371-4. PubMed ID: 26123478 [TBL] [Abstract][Full Text] [Related]
27. Hemolytic anemia following high dose intravenous immunoglobulin in patients with chronic neurological disorders. Markvardsen LH; Christiansen I; Harbo T; Jakobsen J Eur J Neurol; 2014; 21(1):147-52. PubMed ID: 24180709 [TBL] [Abstract][Full Text] [Related]
28. Anti-A and anti-B hemagglutinin depletion during Cohn purification process of 5% immunoglobulin. Salvatore A; Esin S; Batoni G; Ascione E; Farina C; Nardini C Transfusion; 2015 Jul; 55 Suppl 2():S110-6. PubMed ID: 26174888 [TBL] [Abstract][Full Text] [Related]
29. Intravenous immunoglobulin-related hemolysis in patients treated for Kawasaki disease. Luban NL; Wong EC; Henrich Lobo R; Pary P; Duke S Transfusion; 2015 Jul; 55 Suppl 2():S90-4. PubMed ID: 26174904 [TBL] [Abstract][Full Text] [Related]
30. Intravenous immune globulin-related hemolysis: comparing two different methods for case assessment. Taylor E; Vu D; Legare C; Keene D Transfusion; 2015 Jul; 55 Suppl 2():S23-7. PubMed ID: 26174894 [TBL] [Abstract][Full Text] [Related]
31. Pathogenesis and mechanisms of antibody-mediated hemolysis. Flegel WA Transfusion; 2015 Jul; 55 Suppl 2(0):S47-58. PubMed ID: 26174897 [TBL] [Abstract][Full Text] [Related]
32. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Daw Z; Padmore R; Neurath D; Cober N; Tokessy M; Desjardins D; Olberg B; Tinmouth A; Giulivi A Transfusion; 2008 Aug; 48(8):1598-601. PubMed ID: 18466176 [TBL] [Abstract][Full Text] [Related]
33. Massive intravascular haemolysis after high dose intravenous immunoglobulin therapy. Mohamed M; Bates G; Eastley B Br J Haematol; 2013 Mar; 160(5):570. PubMed ID: 23294261 [No Abstract] [Full Text] [Related]
34. Possible mechanisms for intravenous immunoglobulin-associated hemolysis: clues obtained from review of clinical case reports. Padmore R Transfusion; 2015 Jul; 55 Suppl 2():S59-64. PubMed ID: 26174898 [TBL] [Abstract][Full Text] [Related]
35. Randomized trial of anti-D immunoglobulin versus low-dose intravenous immunoglobulin in the treatment of childhood chronic idiopathic thrombocytopenic purpura. El Alfy MS; Mokhtar GM; El-Laboudy MA; Khalifa AS Acta Haematol; 2006; 115(1-2):46-52. PubMed ID: 16424649 [TBL] [Abstract][Full Text] [Related]
36. Potential approaches to prevent uncommon hemolytic side effects of AB0 antibodies in plasma derivatives. Buchta C; Macher M; Höcker P Biologicals; 2005 Mar; 33(1):41-8. PubMed ID: 15713555 [TBL] [Abstract][Full Text] [Related]
37. [Detection and side effects of isoantibodies in intravenously administered immunoglobulin preparations]. Strobel E; Wüllenweber J; Peters J Infusionsther Transfusionsmed; 1995 Feb; 22(1):31-5. PubMed ID: 7727961 [TBL] [Abstract][Full Text] [Related]
39. Anti-A and anti-B haemagglutinin levels in intravenous immunoglobulins: are they on the rise? A comparison of four different analysis methods and six products. Bellac CL; Polatti D; Hottiger T; Girard P; Sänger M; Gilgen M Biologicals; 2014 Jan; 42(1):57-64. PubMed ID: 24325871 [TBL] [Abstract][Full Text] [Related]